Vaxart, Inc. Depreciation and Amortization Expense
Vaxart, Inc. (VXRT) reported Depreciation and Amortization Expense of $1.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DepreciationAndAmortization · last filed 2026-08-06
- Vaxart, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2026-06-30 was $741.00K, a 66.27% decline year-over-year.
- Vaxart, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2026-03-31 was $1.13M, a 49.89% decline year-over-year.
- Vaxart, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2025-12-31 was $2.06M, a 8.09% decline year-over-year.
- Vaxart, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2025-09-30 was $2.08M, a 6.47% decline year-over-year.
- Vaxart, Inc. depreciation, depletion and amortization, nonproduction for fiscal 2023 was $8.62M, a 48.56% increase from fiscal 2022.
- Vaxart, Inc. depreciation, depletion and amortization, nonproduction for fiscal 2022 was $5.80M, a 37.95% increase from fiscal 2021.
- Vaxart, Inc. depreciation, depletion and amortization, nonproduction for fiscal 2021 was $4.21M, a 55.28% increase from fiscal 2020.
- Vaxart, Inc. depreciation, depletion and amortization, nonproduction for fiscal 2020 was $2.71M, a 24.64% decline from fiscal 2019.
| Period end | Depreciation, Depletion and Amortization, Nonproduction 3 month | Depreciation, Depletion and Amortization, Nonproduction 6 month | Depreciation, Depletion and Amortization, Nonproduction 9 month | Depreciation, Depletion and Amortization, Nonproduction 12 month |
|---|---|---|---|---|
| 2026-06-30 | $741.00K derived: 10-Q 6 month − S-1 3 month · filed 2026-08-06 | $1.87M 10-Q · filed 2026-08-06 | $3.92M derived: sum of 3 quarters · filed 2026-08-06 | $6.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.13M S-1 · filed 2026-05-08 | $3.18M derived: sum of 2 quarters · filed 2026-05-08 | $5.26M derived: sum of 3 quarters · filed 2026-05-08 | $7.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.06M derived: S-1 12 month − 10-Q 9 month · filed 2026-05-08 | $4.13M derived: sum of 2 quarters · filed 2026-05-08 | $6.33M derived: sum of 3 quarters · filed 2026-08-06 | $8.58M S-1 · filed 2026-05-08 |
| 2025-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.28M derived: sum of 2 quarters · filed 2026-08-06 | $6.52M 10-Q · filed 2025-11-13 | $8.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.20M derived: 10-Q 6 month − S-1 3 month · filed 2026-08-06 | $4.44M 10-Q · filed 2026-08-06 | $6.68M derived: sum of 3 quarters · filed 2026-08-06 | $8.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.25M S-1 · filed 2026-05-08 | $4.48M derived: sum of 2 quarters · filed 2026-05-08 | $6.71M derived: sum of 3 quarters · filed 2026-05-08 | $8.92M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $2.24M derived: S-1 12 month − 10-Q 9 month · filed 2026-05-08 | $4.46M derived: sum of 2 quarters · filed 2026-05-08 | $6.67M derived: sum of 3 quarters · filed 2026-05-08 | $8.85M S-1 · filed 2026-05-08 |
| 2024-09-30 | $2.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.44M derived: sum of 2 quarters · filed 2025-11-13 | $6.61M 10-Q · filed 2025-11-13 | $8.95M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $4.39M 10-Q · filed 2025-08-13 | $6.72M derived: sum of 3 quarters · filed 2025-08-13 | $8.79M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $2.18M 10-Q · filed 2025-05-13 | $4.51M derived: sum of 2 quarters · filed 2025-05-13 | $6.57M derived: sum of 3 quarters · filed 2025-05-13 | $8.74M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $4.40M derived: sum of 2 quarters · filed 2025-03-20 | $6.56M derived: sum of 3 quarters · filed 2025-03-20 | $8.62M 10-K · filed 2025-03-20 |
| 2023-09-30 | $2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $4.23M derived: sum of 2 quarters · filed 2024-11-13 | $6.29M 10-Q · filed 2024-11-13 | $8.18M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.23M 10-Q · filed 2024-08-08 | $6.12M derived: sum of 3 quarters · filed 2024-08-08 | $7.68M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.06M 10-Q · filed 2024-05-13 | $3.95M derived: sum of 2 quarters · filed 2024-05-13 | $5.51M derived: sum of 3 quarters · filed 2024-05-13 | $6.74M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $3.45M derived: sum of 2 quarters · filed 2024-03-14 | $4.67M derived: sum of 3 quarters · filed 2024-03-14 | $5.80M 10-K · filed 2024-03-14 |
| 2022-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.78M derived: sum of 2 quarters · filed 2023-11-02 | $3.92M 10-Q · filed 2023-11-02 | $5.11M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.35M 10-Q · filed 2023-08-03 | $3.55M derived: sum of 3 quarters · filed 2023-08-03 | $4.57M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $1.13M 10-Q · filed 2023-05-04 | $2.33M derived: sum of 2 quarters · filed 2023-05-04 | $3.35M derived: sum of 3 quarters · filed 2023-05-04 | $4.34M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $2.22M derived: sum of 2 quarters · filed 2023-03-15 | $3.21M derived: sum of 3 quarters · filed 2023-03-15 | $4.21M 10-K · filed 2023-03-15 |
| 2021-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.01M derived: sum of 2 quarters · filed 2022-11-09 | $3.01M 10-Q · filed 2022-11-09 | $3.87M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $993.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.99M 10-Q · filed 2022-08-08 | $2.85M derived: sum of 3 quarters · filed 2022-08-08 | $3.51M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $996.00K 10-Q · filed 2022-05-09 | $1.86M derived: sum of 2 quarters · filed 2022-05-09 | $2.51M derived: sum of 3 quarters · filed 2022-05-09 | $3.13M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $864.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.52M derived: sum of 2 quarters · filed 2022-02-24 | $2.13M derived: sum of 3 quarters · filed 2022-02-24 | $2.71M 10-K · filed 2022-02-24 |
| 2020-09-30 | $653.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.27M derived: sum of 2 quarters · filed 2021-11-04 | $1.85M 10-Q · filed 2021-11-04 | $2.59M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $613.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.19M 10-Q · filed 2021-08-05 | $1.94M derived: sum of 3 quarters · filed 2022-02-24 | $2.69M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $580.00K 10-Q · filed 2021-05-06 | $1.32M derived: sum of 2 quarters · filed 2022-02-24 | $2.08M derived: sum of 3 quarters · filed 2022-02-24 | $3.08M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $742.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.50M derived: sum of 2 quarters · filed 2022-02-24 | $2.50M derived: sum of 3 quarters · filed 2022-02-24 | $3.60M 10-K · filed 2022-02-24 |
| 2019-09-30 | $757.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.75M derived: sum of 2 quarters · filed 2020-11-12 | $2.85M 10-Q · filed 2020-11-12 | $3.68M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $997.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.10M 10-Q · filed 2020-08-06 | $2.92M derived: sum of 3 quarters · filed 2021-02-25 | $3.86M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $1.10M 10-Q · filed 2020-05-12 | $1.92M derived: sum of 2 quarters · filed 2021-02-25 | $2.87M derived: sum of 3 quarters · filed 2021-02-25 | $3.79M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $824.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.77M derived: sum of 2 quarters · filed 2021-02-25 | $2.69M derived: sum of 3 quarters · filed 2021-02-25 | $3.20M 10-K · filed 2021-02-25 |
| 2018-09-30 | $942.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $1.87M derived: sum of 2 quarters · filed 2019-11-12 | $2.38M 10-Q · filed 2019-11-12 | $2.46M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $926.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $1.44M 10-Q · filed 2019-08-08 | $1.52M derived: sum of 3 quarters · filed 2019-08-08 | $1.61M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $511.00K 10-Q · filed 2019-05-09 | $596.00K derived: sum of 2 quarters · filed 2019-05-09 | $688.00K derived: sum of 3 quarters · filed 2019-05-09 | $794.00K derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $177.00K derived: sum of 2 quarters · filed 2019-02-06 | $283.00K derived: sum of 3 quarters · filed 2019-02-06 | $380.00K 10-K · filed 2019-02-06 |
| 2017-09-30 | $92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $198.00K derived: sum of 2 quarters · filed 2018-11-13 | $295.00K 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $203.00K 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | $97.00K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |